Asherman's syndrome epidemiology and demographics
|
Asherman's syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Asherman's syndrome epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Asherman's syndrome epidemiology and demographics |
|
Asherman's syndrome epidemiology and demographics in the news |
|
Risk calculators and risk factors for Asherman's syndrome epidemiology and demographics |
Editor(s)-in-Chief: Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Canan S Fornusek, Ph.D.; Associate Editor-In-Chief: Saud Khan M.D.
Overview
Epidemiology and Demographics
The true prevalence of Asherman’s syndrome is unclear. The condition is estimated to affect 1.5% of women undergoing HSG [1], between 5 and 39% of women with recurrent miscarriage [2][3][4] and up to 40% of patients who have undergone D&C for retained products of conception [5]. It may occur in up to 13% of women undergoing a termination of pregnancy during the first trimester, and 30% in women undergoing a dilation and curettage (D and C) after a late spontaneous abortion.
Women with placental abnormalities (e.g., placenta increta) may have a higher risk of developing Asherman syndrome as the placenta adheres to deeper layers within the uterus and becomes more difficult to remove. The incidence may be as high as 23.4% in patients undergoing procedures two to four weeks after the initial procedure for a vaginal delivery or missed abortion. The risk increases for patients undergoing repeated procedures for bleeding or repeated elective termination of pregnancies.
It is found in 1.5% of women evaluated with a hysterosalpingogram (HSG) for infertility, between 5 and 39% of women with recurrent miscarriage. Asherman’s Syndrome may occur in 31% of women after the initial hysteroscopic resection of leiomyoma, and up to 46% after the second hysteroscopic resection.[6][7]
References
- ↑ Dmowski WP, Greenblatt RB. (1969). "Asherman's syndrome and risk of placenta accreta". Obstet Gynecol. 34 (2): 288–299. PMID 5816312.
- ↑ Rabau E, David A. (1963). "Intrauterine adhesions:etiology, prevention, and treatment". Obstet Gynecol. 22: 626–629. PMID 14082285.
- ↑ Toaff R. (1966). "Some remarks on posttraumatic uterine adhesions.in French". Rev Fr Gynecol Obstet. 61 (7): 550–552. PMID 5940506.
- ↑ Ventolini G, Zhang M, Gruber J. (2004). "Hysteroscopy in the evaluation of patients with recurrent pregnancy loss: a cohort study in a primary care population". Surg Endosc. 18 (12): 1782–1784. doi:10.1007/s00464-003-8258-y. PMID 15809790.
- ↑ Westendorp ICD, Ankum WM, Mol BWJ, Vonk J. (1998). "Prevalence of Asherman's syndrome after secondary removal of placental remnants or a repeat curettage for incomplete abortion". Hum Reprod. 13 (12): 3347–3350. doi:10.1093/humrep/13.12.3347. PMID 9886512.
- ↑ Chikazawa K, Imai K, Liangcheng W, Sasaki S, Horiuchi I, Kuwata T; et al. (2018). "Detection of Asherman's syndrome after conservative management of placenta accreta: a case report". J Med Case Rep. 12 (1): 344. doi:10.1186/s13256-018-1869-7. PMC 6245912. PMID 30454053.
- ↑ Tchente NC, Brichant G, Nisolle M (2018) [Asherman's syndrome : management after curettage following a postnatal placental retention and literature review.] Rev Med Liege 73 (10):508-512. PMID: 30335256